High-Density Lipoprotein Functionality in Coronary Artery Disease

被引:34
|
作者
Kosmas, Constantine E. [1 ]
Christodoulidis, Georgios [2 ]
Cheng, Jeh-wei [3 ]
Vittorio, Timothy J. [4 ]
Lerakis, Stamatios [3 ]
机构
[1] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA
[2] Winthrop Univ Hosp, Dept Internal Med, Mineola, NY 11501 USA
[3] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA
[4] St Francis Hosp Heart Ctr, Div Cardiol, Ctr Adv Cardiac Therapeut, Roslyn, NY USA
关键词
High-density lipoprotein functionality; High-density lipoprotein particles; Cardiovascular risk; Apolipoprotein A-1 Milano; Cholesteryl ester transfer protein inhibitors; Cholesterol efflux capacity; ESTER TRANSFER PROTEIN; APOLIPOPROTEIN-A-I; REVERSE CHOLESTEROL TRANSPORT; CARDIOVASCULAR-DISEASE; ANTIINFLAMMATORY PROPERTIES; HDL CHOLESTEROL; VASCULAR EVENTS; HIGH-RISK; ATHEROSCLEROSIS; METABOLISM;
D O I
10.1097/MAJ.0000000000000231
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The role of high-density lipoprotein (HDL) in cardiovascular atheroprotection is well established. Epidemiological data have clearly demonstrated an inverse relationship between HDL levels and the risk for coronary artery disease, which is independent of the low-density lipoprotein levels. However, more recent data provide evidence that high HDL levels are not always protective and that under certain conditions may even confer an increased risk. Thus, a new concept has arisen, which stresses the importance of HDL functionality, rather than HDL concentration per se, in the assessment of cardiovascular risk. HDL functionality is genetically defined but can also be modified by several environmental and lifestyle factors, such as diet, smoking or certain pharmacologic interventions. Furthermore, HDL is consisted of a heterogeneous group of particles with major differences in their structural, biological and functional properties. Recently, the cholesterol efflux capacity from macrophages was proven to be an excellent metric of HDL functionality, because it was shown to have a strong inverse relationship with the risk of angiographically documented coronary artery disease, independent of the HDL and apolipoprotein A-1 levels, although it may not actually predict the prospective risk for cardiovascular events. Thus, improving the quality of HDL may represent a better therapeutic target than simply raising the HDL level, and assessment of HDL function may prove informative in refining our understanding of HDL-mediated atheroprotection.
引用
收藏
页码:504 / 508
页数:5
相关论文
共 50 条
  • [21] Paradoxical coronary artery disease in humans with hyperalphalipoproteinemia is associated with distinct differences in the high-density lipoprotein phosphosphingolipidome
    Hancock-Cerutti, William
    Lhomme, Marie
    Dauteuille, Carolane
    Lecocq, Sora
    Chapman, John
    Rader, Daniel J.
    Kontush, Anatol
    Cuchel, Marina
    JOURNAL OF CLINICAL LIPIDOLOGY, 2017, 11 (05) : 1192 - 1200
  • [22] Total cholesterol/high-density lipoprotein cholesterol and low-density lipoprotein cholesterol/high-density lipoprotein cholesterol as predictors of coronary artery calcification assessed by multidetector computed tomography coronary angiography
    Seaoud, Elshaimaa Aly M. Elsadek
    Amin, Mohamed Ibrahim
    Abdelbasit, Mohamed Salah
    ARYA ATHEROSCLEROSIS, 2022, 18
  • [23] Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease
    Krychtiuk, Konstantin A.
    Kastl, Stefan P.
    Pfaffenberger, Stefan
    Pongratz, Thomas
    Hofbauer, Sebastian L.
    Wonnerth, Anna
    Katsaros, Katharina M.
    Goliasch, Georg
    Gaspar, Ludovit
    Huber, Kurt
    Maurer, Gerald
    Dostal, Elisabeth
    Oravec, Stanislav
    Wojta, Johann
    Speidl, Walter S.
    ATHEROSCLEROSIS, 2014, 237 (02) : 589 - 596
  • [24] Speciated High-Density Lipoprotein Biogenesis and Functionality
    Rosales, C.
    Davidson, W. S.
    Gillard, B. K.
    Gotto, A. M., Jr.
    Pownall, H. J.
    CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (05)
  • [25] Acute high-density lipoprotein therapies
    MyNgan Duong
    Di Bartolo, Belinda A.
    Nicholls, Stephen J.
    CURRENT OPINION IN LIPIDOLOGY, 2015, 26 (06) : 521 - 525
  • [26] Reduced high-density lipoprotein antioxidant function in patients with coronary artery disease and acute coronary syndrome
    Sasko, Benjamin
    Scharow, Linda
    Mueller, Rhea
    Jaensch, Monique
    Dammermann, Werner
    Seibert, Felix S.
    Hillmeister, Philipp
    Buschmann, Ivo
    Christ, Martin
    Ritter, Oliver
    Hamdani, Nazha
    Ukena, Christian
    Westhoff, Timm H.
    Kelesidis, Theodoros
    Pagonas, Nikolaos
    JCI INSIGHT, 2025, 10 (06)
  • [27] High-density lipoprotein subclasses and their relationship to cardiovascular disease
    Superko, H. Robert
    Pendyala, Lakshmana
    Williams, Paul T.
    Momary, Katherine M.
    King, Spencer B., III
    Garrett, Brenda C.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2012, 6 (06) : 496 - 523
  • [28] Relationship between the neutrophil to high-density lipoprotein cholesterol ratio and severity of coronary artery disease in patients with stable coronary artery disease
    Gao, Jie
    Lu, Jun
    Sha, Wenjun
    Xu, Bilin
    Zhang, Cuiping
    Wang, Hongping
    Xia, Juan
    Zhang, Hong
    Tang, Wenjun
    Lei, Tao
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [29] High-density lipoprotein subclass profile and mortality in patients with coronary artery disease: Results from the GENES study
    Elbaz, Meyer
    Faccini, Julien
    Bongard, Vanina
    Ingueneau, Cecile
    Taraszkiewicz, Dorotea
    Perret, Bertrand
    Ferrieres, Jean
    Ruidavets, Jean-Bernard
    Vindis, Cecile
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2016, 109 (11) : 607 - 617
  • [30] High-Density Lipoprotein Particle Number A Better Measure to Quantify High-Density Lipoprotein?
    deGoma, Emil M.
    Rader, Daniel J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (06) : 517 - 520